GlaxoSmithKline’s $500 million portfolio with Avalon Ventures invested in its in first startup – Palo Alto-based Sitari Pharmaceuticals.
According to Fierce Biotech, the San Diego-based venture group and its partners at GSK are funding Sitari with $10 million in cash and research support, with the R&D assist coming from the pharma giant.
{iframe}http://www.baybioinstitute.org/bay-area-startup-benefits-from-gsk-portfolio-deal/{/iframe}